Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (PAS-25-190)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-25-225)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional) (PAR-25-219)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) (PAR-25-036)

Sponsor: National Institute of Mental Health, National Institute on Aging

Due Date: Multiple due dates; see announcement.

NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed) (RFA-NS-25-019)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: Application budgets need to reflect the actual needs of the proposed project; however, it is anticipated that most awards will be between $150,000-$800,000 direct costs per year, commensurate with the scope of the proposed program. The maximum project period is 3 years.

Due Date: Application due October 17, 2025. Letter of intent due 30 days prior to application.

Translational Neural Devices (R61/R33 - Clinical Trial Optional) (PAR-25-053)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) (PAR-25-122)

Sponsor: National Institutes of Health

Award: Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.

Due Date: Multiple due dates; see announcement.

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) (PAR-25-024)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) (PAR-24-268)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R01 Clinical Trial Optional) (PAR-25-2

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) (RFA-MH-26-140)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-25-058)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) (PAR-25-059)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) (PAR-25-0

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional) (NOT-OD-25-015)

Sponsor: National Institutes of Health

Due Date: January 24, 2025.